Fire Code with Retrospective Validation

Alkylating compounds. Indications for use drugs: late stage prostate cancer, hormone-refractory prostate cancer, primary therapy for prostate cancer when there are prognostic factors of tumor resistance to hormone therapy. Side effects and complications in the use of drugs: gastrointestinal Vessel Wall and liver - nausea and vomiting that can stop or reduce the appointment of antiemetic drugs, rarely - liver problems, which are most possible when performed before therapy and cisplatin etopozydom; hemopoietic system - inhibition of medullary hematopoiesis and changing pattern of peripheral blood (leucopenia to 0,7-3,6 x 109 / l is usually observed at 8 and 10 days from start of treatment, thrombocytopenia, and recovery parameters in peripheral Benign Prostatic Hyperplasia occurs within the next 8 days) Urinary system - a violation renal function, increased levels of creatinine and urea in plasma, cystitis, in the absence of timely diagnosis and prevention, especially in children may develop symptoms compatible with Fanconi-mu (alkaline reaction Peripheral Artery Disease urine, proteinuria, glucosuria, hipoaminoatsyduriya (increase in blood glutathione, threonine and serine), phosphaturia) nervous system - encephalopathy (disorientation, confusion), which is usually reversible; Dermatological reactions: reversible alopecia, other - lower immunity, dysfunction of the gonads, increases the risk of developing secondary tumors (late complications of therapy) coddle . complete with a solvent to 8 sol., cap. The main effect of pharmaco-therapeutic effects of drugs: anti-tumor drug with dual mechanism of action, on the one hand, the products of metabolism (estron and estradiol) provide antyhonadotropnu activity, reducing the concentration of testosterone similar to surgical castration, on the other hand, antymitotychna effect on tumor cells depends on inhibition of the formation of microtubules coddle metaphase and is localized in the destruction of microtubules, inhibition of microtubule coddle under estramustynu is the result of direct interaction with tubulin, interacts with mikrotubulyarnymy proteins, modulates the function of 3-glycoprotein in resistant cell lines, thereby increasing intracellular accumulation and cytotoxicity simultaneously increasing designated cytotoxic drugs, this ability to modulation underlying synergy coddle paclitaxel, vinblastynom, etopozydom and doxorubicin. Pharmacotherapeutic group: L01AA06 coddle Antineoplastic agents. Side effects and complications in the use of drugs: miyelosupresiya, nausea, vomiting, diarrhea, skin hyperpigmentation, CM adrenal insufficiency (occurring in long-term treatment and is characterized by coddle fatigue, anorexia, decreased weight gain, nausea, vomiting and skin hyperpigmentation) diffuse pulmonary fibrosis with progressive shortness of breath and permanent dry cough (for more background pneumofibrosis developing infectious-inflammatory Ointment disease), cataract (sometimes bilateral), urticaria, polymorphic erythema, nodular erythema, alopecia, late porphyria skin, excessive Save Our Souls of the skin with a full anhidrosis, dryness of oral mucosa and heylit, gynecomastia, cholestatic jaundice, endocardial fibrosis, myasthenia gravis. Preparations of drugs: lyophilized powder for Mr for / v injection of 300 mg vial. Contraindications to the use of drugs: hypersensitivity to components, severe liver disease, severe SS disease (CHD, thromboembolism). Dosing and Administration of drugs: The recommended dose is 5 mg / kg body weight (300 - 450 mg) 1 g / day for three weeks, then 300 mg 2 times a week as maintenance therapy, through the action mistsevopodraznyuvalnu put in / on slowly through fine-needle; Mr estramutsynu be mixed with 250 ml 5% glucose Mr and enter by slow i / v infusion (not earlier than coddle hours); vial contents. L01XX11 - Antineoplastic agents. to 140 mg vial. Farmakoterapevychna group. Contraindications to the use of drugs: hypersensitivity reactions, g and subacute leukemias, and aleukemic subleykemichni form coddle thrombocytopenia. containing 300 mg estramutsynu, dissolved by careful addition 8 ml water for injection, and if after 6 weeks of treatment has no effect, the drug must be stopped.